Savara (NASDAQ:SVRA) Sees Strong Trading Volume – Still a Buy?

Shares of Savara Inc. (NASDAQ:SVRA) saw unusually-high trading volume on Friday . Approximately 1,314,910 shares changed hands during mid-day trading, a decline of 8% from the previous session’s volume of 1,435,789 shares.The stock last traded at $6.4250 and had previously closed at $6.37.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on Savara in a research note on Monday, October 20th. They issued an “overweight” rating and a $7.00 target price on the stock. Citizens Jmp reduced their target price on Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a report on Thursday, November 13th. Lifesci Capital upgraded Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. Finally, JMP Securities increased their price target on shares of Savara from $8.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.29.

Savara Price Performance

The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -12.14 and a beta of 0.23. The company has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $3.27. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Research analysts expect that Savara Inc. will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Savara

Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its holdings in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Savara during the 3rd quarter worth about $44,000. Prudential Financial Inc. acquired a new stake in Savara during the 2nd quarter worth about $30,000. BNP Paribas Financial Markets grew its stake in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Finally, May Hill Capital LLC acquired a new position in shares of Savara in the second quarter valued at about $32,000. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.